Joachim Stangier

Idarucizumab for Dabigatran Reversal

Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +4

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Charles V. Pollack, Paul Reilly, Joanne van Ryn et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

Joachim Stangier, Karin Rathgen, Hildegard Stähle et al. · British Journal of Clinical Pharmacology · 2007 · 884 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

Joachim Stangier, Karin Rathgen, Hildegard Stähle et al. · Clinical Pharmacokinetics · 2010 · 722 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans

Stefan Blech, Thomas Ebner, Eva Ludwig-Schwellinger et al. · Drug Metabolism and Disposition · 2007 · 682 citations

Pharmacy, Pharmacokinetics, Pharmacology +14